HIGH-INTENSITY INDUCTION THERAPY COMBINING TOFACITINIB, RITUXIMAB, AND PLASMAPHERESIS IN RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5 ANTIBODY POSITIVE DERMATOMYOSITIS
HIGH-INTENSITY INDUCTION THERAPY COMBINING TOFACITINIB, RITUXIMAB, AND PLASMAPHERESIS IN RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5 ANTIBODY POSITIVE DERMATOMYOSITIS
复制标题
托法替尼、利妥昔单抗和血浆置换联合高强度诱导治疗与抗 MDA5 抗体阳性皮肌炎相关的快速进展间质性肺病
DOI：
--
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Ishii T
中科院分区：
文献类型：
--
作者：
Shirai T;Sato H;Fujii H;Ishii T
